Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL6858082 | 0.95 | LMNA (0.49) | LMNAMAPTCES2MEN1KMT2A | |
| SCHEMBL21802732 | 0.92 | LMNA (0.47) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL2498627 | 0.87 | LMNA (0.49) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL11589631 | 0.85 | LMNA (0.47) | LMNAMAPTMEN1KMT2A | |
| SCHEMBL4653090 | 0.84 | MAPT (0.42) | LMNAMAPTCES2MEN1KMT2A | |
| SCHEMBL27780045 | 0.83 | LMNA (0.52) | LMNAMAPTCES2MEN1KMT2A | |
| SCHEMBL20747697 | 0.83 | LMNA (0.52) | LMNAMAPTCES2MEN1KMT2A | |
| SCHEMBL20747681 | 0.83 | LMNA (0.52) | LMNAMAPTCES2MEN1KMT2A | |
| SCHEMBL11221807 | 0.83 | PRKCE (0.42) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL22852129 | 0.81 | LMNA (0.50) | LMNAMAPTCES2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110040078-A1 | PROCESS FOR THE PRODUCTION OF TELITHROMYCIN | Wolf, Siegfried (AT) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040078-A1 | PROCESS FOR THE PRODUCTION OF TELITHROMYCIN | TREH, EEF2, TCERG1 | LMNA 2024/4885MAPT 901/4885CES2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.